



Date: 28/01/2022

BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400 001 Script Code : 539872	National Stock Exchange of India Limited 5th Floor, Exchange Plaza, Bandra Kurla Complex, Bandra (East) Mumbai-400 051 Script Code: BAJAJHCARE
---	--

Dear Sir/Madam,

Sub: Outcome of Board Meeting & submission of Unaudited Financial Results for the quarter/ Nine Months ended December 31, 2021.

The Board of Directors at its Meeting held today has inter alia:

- Approved the unaudited Financial Statements for the quarter / nine months ended December 31, 2021, as recommended by the Audit Committee; and

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015, we enclose herewith the following:

- (i) Unaudited Financial Results for the quarter and nine months ended December 31, 2021 along with limited review report;

The above information is also available on the Company's website at www.bajajhealth.com. This is for your information and records.

We wish to inform you that Board Meeting commenced today at 01.30 p.m. and concluded at 2.15 p.m.


Kindly take the same on record.

Thanking you,

Yours faithfully,

For and on behalf of Board of Directors
of Bajaj Healthcare Limited

Mr. Aakashkumar Keshari
Company Secretary



Encl: a/a

BAJAJ HEALTHCARE LIMITED

Registered Office : 602-606, Bhoomi Velocity Infotech Park, Plot No. B-39, B-39/A, B-39 A/1, Road No. 23, Wagle Ind. Estate, Thane(West), Thane-400 604.

• Tel. : + 91 22 6617 7400 - 499 • Fax : + 91 22 66177458 • Website : www.bajajhealth.com

CIN No.: L99999MH1993PLC072892

Chaturvedi & Agrawal


Chartered Accountants

Independent Auditor's Review Report on the Quarter and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
Bajaj Healthcare Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of Bajaj Healthcare Limited (the "Company") for the quarter ended December 31, 2021 and year to date from April 01, 2021 to December 31, 2021 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in applicable Indian Accounting Standards 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Chaturvedi & Agrawal
Chartered Accountants
FRN: 101717W




Rasik Chaturvedi

Partner

M. no: 039524

UDIN: 22039524AAAAAB3991



Date: January 28, 2022

Place: Thane



BAJAJ HEALTHCARE LIMITED
(CIN No. : L99999MH1993PLC072892)
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED ON 31ST DECEMBER, 2021
(Rs. In Lakhs Except for Earnings Per Share)


Particulars	Quarter Ended			Nine Month Ended		Year Ended
	31.12.2021	30.09.2021	31.12.2020	31.12.2021	31.12.2020	31.03.2021
	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I. Revenue from operations	16,757.49	15,091.25	17,833.44	50,417.62	52,480.23	65,698.38
II. Other Income	19.81	11.84	176.35	99.60	476.02	691.26
III. Total Revenue (I+II)	16,777.30	15,103.09	18,009.79	50,517.22	52,956.25	66,389.64
IV. Expenses						
(a) Cost of materials consumed (Including Other Direct Expenses)	8,876.40	11,498.42	11,802.07	35,819.06	37,614.06	46,342.49
(b) Changes in Inventories of Finished Good	3,121.48	(699.72)	314.14	429.20	130.12	70.18
(c) Employee benefits expense	1,130.99	929.08	871.16	3,024.41	2,650.26	3,454.87
(d) Finance Costs	284.47	249.96	192.41	813.76	614.41	829.60
(d) Depreciation and amortisation expense	485.88	440.74	395.53	1,339.69	1,169.54	1,612.42
(e) Other expenses	545.54	466.93	440.81	1,815.53	1,915.08	2,198.12
Total Expenses	14,444.76	12,885.41	14,016.12	43,241.64	44,093.48	54,507.67
V. Profit Before Tax	2,332.54	2,217.68	3,993.67	7,275.58	8,862.77	11,881.97
VI. Tax Expense						
(a) Current tax	597.00	454.00	1,400.00	1,865.00	2,800.00	3,497.41
(b) Earlier Years	-	2.13	-	2.04	-	23.73
(c) Deferred Tax	-8.99	36.40	-48.61	17.14	-120.34	49.93
Total Tax Expenses	588.01	492.53	1,351.39	1,884.18	2,679.66	3,571.07
VII. Profit (Loss) for the Period	1,744.53	1,725.15	2,642.28	5,391.39	6,183.11	8,310.89
VIII. Other comprehensive Income						
(i) Items that will not be reclassified to profit or loss*	-	-	-	-	-	(30.46)
(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	8.87
(iii) Items that will be reclassified to profit or loss	-	-	-	-	-	-
(iv) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
Total Comprehensive Income for the Period	1,744.53	1,725.15	2,642.28	5,391.39	6,183.11	8,289.31
IX. Paid-up Equity Share Capital (Face Value Rs. 5/-)	1,379.92	1,379.92	1,379.92	1,379.92	1,379.92	1,379.92
X. Other Equity excluding Revaluation Reserve	-	-	-	-	-	24,461.13
XI. Earnings Per Share (Face Value Rs. 5/-) (Not Annualised for Quarter and Nine Months)						
(a) Basic (in Rs.)	6.32	6.25	9.57	19.54	22.40	30.11
(b) Diluted (in Rs.)	6.32	6.25	9.57	19.54	22.40	30.11
Dividend Declared during the Year:						
Interim Dividend (Per Share)	-	-	-	-	-	1.25
Special Dividend (Per Share)	-	-	-	-	-	1.00
Final Dividend (Per Share)	-	-	-	-	-	0.50
Total Dividend (Per Share)	-	-	-	-	-	2.75
Cumulative Dividend Percentage	-	-	-	-	-	27.50%

Note :

- a) The above Financial Results have been reviewed by the Audit Committee and subsequently approved by Board of Directors at their respective meetings held on January 28, 2022
- b) The financial results for the Quarter and Nine Months Ended December 31, 2021 have been subjected to limited review by the statutory auditors of the Company.
- c) The Statement as per IND AS - 108 on segment reporting is given as Annexure-A.
- d) Figures of previous period have been regrouped/reclassified, wherever necessary, to make them comparable and to conform with current period classification.
- e) Pursuant to the approval of the shareholders by way of Postal Ballot on September 17, 2021, Equity Share of Rs. 10/- each fully paid up was sub divided into 2 Equity Shares of Rs. 5/- each fully paid up, with effect from the record date September 29, 2021. Consequently, the basic and diluted earnings per share have been adjusted retrospectively for all the periods presented in the Standalone Financial Results of the Company on the basis of the new number of equity shares in accordance with the provisions of applicable Ind AS.
- f) Cumulative Dividend Percentage is Calculated based on Face Value prevalent at the time of declaration of Dividend i.e. Rs. 10/- per Equity Share. The Corresponding Dividend Cumulative Dividend percentage pursuant to Split of the Equity Shares of the Company is 55% on face value of Rs. 5/- per Equity Share.

By Order of the Board
For Bajaj Healthcare Limited

Mr. Sajankumar R Bajaj
D.No.: 00225950
Chairman and Managing Director



Date: January 28, 2022
Place: Thane

BAJAJ HEALTHCARE LIMITED

(CIN No. : L99999MH1993PLC072892)

REPORT ON SEGMENT RESULTS FOR QUARTER AND NINE MONTH ENDED ON 31ST DECEMBER, 2021

Annexure : A

(Rs. In Lakhs)

Sr No	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31.12.2021	30.09.2021	31.12.2020	31.12.2021	31.12.2020	31.03.2021
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
A	Segment Revenue (Excluding Intersegment Revenue)						
	Bulk Drugs	15906.58	13741.05	16601.45	43176.35	46612.58	59336.46
	Formulations	850.91	1350.20	1231.99	7241.27	5867.65	6361.92
	Total	16,757.49	15,091.25	17,833.44	50,417.62	52,480.23	65,698.38
	InterSegment Revenue						
	Bulk Drugs	1423.53	1,511.41	488.54	7,357.10	2,315.69	2,586.87
	Formulations	0.00	-	7.53	615.12	40.73	210.83
	Total	1,423.53	1,511.41	496.07	7,972.21	2,356.42	2,797.69
	Gross Segment Revenue (Including Intersegment Revenue)						
	Bulk Drugs	17330.11	15252.46	17089.99	50533.44	48928.27	61923.32
Formulations	850.91	1350.20	1239.51	7856.38	5908.38	6572.75	
Total	18,181.02	16,602.66	18,329.51	58,389.83	54,836.65	68,496.07	
B	II. Segment Results						
	Profit / (Loss) Before Tax & Finance Cost						
	Bulk Drugs	2954.81	2,848.54	4,459.29	9,298.84	10,478.42	13,924.25
	Formulations	207.74	86.03	152.25	606.02	973.44	985.43
	Total	3,162.55	2,934.57	4,611.54	9,904.86	11,451.86	14,909.68
Less : Interest	284.47	249.96	192.41	813.76	614.41	829.60	
Other Unallocable Expenditure (Net)	545.54	466.93	425.46	1,815.53	1,974.68	2,198.12	
Total Profit Before Tax	2,332.54	2,217.68	3,993.68	7,275.58	8,862.77	11,881.97	
C	I. Segment Assets						
	Bulk Drugs	64,651.38	60,655.53	44,887.34	64,651.38	44,887.34	50,063.51
	Formulations	5,670.49	5,006.48	3,003.83	5,670.49	3,003.83	2,499.35
	Others	0.31	0.31	500.31	0.31	500.31	0.31
	Total	70,322.18	65,662.32	48,391.47	70,322.18	48,391.47	52,563.17
	II. Segment Liabilities						
	Bulk Drugs	37,888.37	34,687.79	23,150.11	37,888.37	23,150.11	25,743.74
	Formulations	825.71	947.16	689.87	825.71	689.87	484.92
	Others	513.64	539.45	824.07	513.64	824.07	493.46
	Total	39,227.73	36,174.41	24,664.04	39,227.73	24,664.04	26,722.12
Total Capital Employed	31,094.45	29,487.91	23,727.43	31,094.45	23,727.43	25,841.05	
Total (II+III)	70,322.18	65,662.32	48,391.47	70,322.18	48,391.47	52,563.17	

By Order of the Board
For Bajaj Healthcare Limited

Place : Thane
Date: January 28, 2022

Mr. Sajankumar R Bajaj
D.No.: 00225950
Chairman and Managing Director

